Department of Pharmacy, First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China.
Can Respir J. 2020 Nov 18;2020:8572636. doi: 10.1155/2020/8572636. eCollection 2020.
Inhalation therapy is the main treatment for asthma and chronic obstructive pulmonary disease (COPD) patients. Owing to the poor inhaler technique in using inhalers, we assessed the effect of a multidimensional pharmaceutical care on inhalation technique in patients with asthma and COPD.
A 3-month controlled parallel-group study was undertaken in asthma and COPD patients using dry powder inhalers (DPIs). Patients in the intervention group received multidimensional pharmaceutical care, including establishment of a special dispensing window, face-to-face demonstration and education, brochure education, videos education, online consultation and education, and follow-up reeducation. Patients in the control group received usual pharmaceutical care. The inhaler technique score, correctness of inhaler usage, beliefs about medicines questionnaire (BMQ) score, asthma control test (ACT), and COPD assessment test (CAT) were measured pre- and postintervention. Quality of life improvement evaluated according to score changes of ACT in asthma and CAT in COPD and patient satisfaction were measured postintervention.
259 patients finished the study with 133 in the intervention group and 126 in the control group. Compared to preintervention and control group postintervention, the inhaler technique score, correctness of inhaler usage, and ACT score significantly increased in the intervention group postintervention, while the BMQ score and CAT score decreased significantly ( < 0.05). Significant improvements in quality of life and patient satisfaction were found ( < 0.05).
This study showed the multidimensional pharmaceutical care for asthma and COPD patients were effective in improving inhalation technique. By providing pharmaceutical care, pharmacists might help asthma and COPD patients to acquire better quality of life.
吸入疗法是哮喘和慢性阻塞性肺疾病（COPD）患者的主要治疗方法。由于患者使用吸入器的吸入技术较差，我们评估了多维药物治疗对哮喘和 COPD 患者吸入技术的影响。
在使用干粉吸入器（DPIs）的哮喘和 COPD 患者中进行了为期 3 个月的对照平行组研究。干预组患者接受多维药物治疗，包括建立特殊配药窗口、面对面演示和教育、宣传册教育、视频教育、在线咨询和教育以及随访再教育。对照组患者接受常规药物治疗。在干预前后测量吸入器技术评分、吸入器使用正确性、药物信念问卷（BMQ）评分、哮喘控制测试（ACT）和 COPD 评估测试（CAT）。根据 ACT 在哮喘和 CAT 在 COPD 中的评分变化评估生活质量改善情况，并在干预后测量患者满意度。
259 例患者完成了研究，其中干预组 133 例，对照组 126 例。与干预前和对照组相比，干预组在干预后吸入器技术评分、吸入器使用正确性和 ACT 评分显著提高，而 BMQ 评分和 CAT 评分显著降低（<0.05）。生活质量和患者满意度均有显著改善（<0.05）。
本研究表明，对哮喘和 COPD 患者进行多维药物治疗可有效改善吸入技术。通过提供药物治疗，药剂师可能有助于哮喘和 COPD 患者获得更好的生活质量。
